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ABSTRACT
We estimated the effect of CD34 stem cell dose during peripheral blood stem cell transplantation (PBSCT) in
predicting mortality after total body irradiation (TBI). Between 1997 and 2004, 146 consecutive patients with
hematologic malignancies received fractionated TBI (12-13.6 Gy) in 8 fractions over 4 days before undergoing
PBSCT; 61 patients received TBI with reduced radiation dose to the lung (6-9 Gy). The number of CD34 cells
transplanted was recorded for all patients. A cubic spline representation for CD34 dose within a Cox proportional
hazards model was used to model the relationship between the CD34 dose and mortality. Median follow-up was
44 months (range, 12–90 months). The CD34 cell dose ranged from 2.45 to 15.90 106 cells/kg (median, 5.15
106 cells/kg). Risk ofmortality decreasedwithCD34 doses between 4–8 106 cells/kg and then began to increase.
For all patients, CD34 doses of 5.1–12.9 106/kg resulted in at least a doubling of median survival associated with
the lowest CD34 value. In patients treated with lung dose reduction, a similar range of CD34 dose (4.3–10.2 
106 cells/kg) produced at least a 5-fold improvement from the survival associated with the lowest CD34 dose;
however, the relationship between CD34 dose and mortality was not statistically different when analyzed by lung
dose reduction. A method for assessing risk of mortality by CD34 dose as a continuous variable is presented. Risk
of mortality decreased with CD34 doses between 4-8  106 cells/kg and then began to increase.
© 2007 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
Peripheral blood stem cell transplantation (PBSCT)
s a key component in the treatment of various malig-
ancies [1-5]. Preparatory regimens for PBSCT often
nclude total body irradiation (TBI) [5-7]. Increasing
umbers of CD34 stem cells given during transplanta-
ion are reported to correlate with decreasing time to
ngraftment [8-10]. This effect is retained until a given
hreshold dose, beyond which no extra beneﬁt occurs
10]. Relatively higher CD34 doses are reported to be
ssociated with increased incidence of chronic graft-ver-
us-host disease (GVHD) [11-13]; however, the effect of
elatively higher CD34 stem cell dose on survival re-
ains unclear [12-15].
A preliminary analysis of this cohort, using theedian dose as a cutpoint, showed that CD34 cell uose was a risk factor for pulmonary transplantation–
elated mortality (relative risk [RR]  9.4 for a
D34 dose  5  106 cells/kg [16]. Lung dose–
educed TBI has also been shown to improve survival
n certain patients with poor pretreatment pulmonary
unction test values [17].
The present analysis was performed to estimate
he effect of CD34 stem cell dose (as a continuous
ariable) during PBSCT in predicting all-cause mor-
ality after TBI performed with or without dose re-
uction to the lung.
ETHODS
tudy Group
Between July 1997 and August 2004, 146 consec-
tive patients with hematologic malignancies under-
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A. K. Singh et al.340ent T-cell–depleted PBSCT from a HLA-identical
ibling in 5 successive National Heart, Lung, and
lood Institute Institutional Review Board–approved
rotocols (97-H-0099, 99-H-0046, 02-H-0111, 03-
-0192, and 04-H-0112).
onditioning Regimens
Three conditioning regimens were used in con-
ecutive time periods. Regimen A (April 1997-De-
ember 2001) consisted of 13.6 Gy of TBI and
yclophosphamide 120 mg/kg, with no lung dose
eduction (n  85). Regimen B (February 2002-May
003) consisted of 12.0 Gy of TBI, with 9.0 Gy to
he lungs, cyclophosphamide 120 mg/kg, and ﬂu-
arabine 125 mg/m2 (n  35). Regimen C (June
003-August 2004) consisted of 12.0 Gy of TBI,
ith 6.0 Gy to the lungs, cyclophosphamide 120
g/kg, and ﬂudarabine 125 mg/m2 (n  26).
adiation Techniques
The radiation techniques used in this cohort have
een described previously [17].
ransplantation Approach
In the ﬁrst protocol, patients received a T-cell–
epleted granulocyte colony-stimulating factor (G-
SF)-mobilized PBSCT using the Ceprate selection
ystem (CellPro, Bothell, WA). Subsequent protocols
sed an Isolex 300 cell separator (Baxter, Deerﬁeld,
L), as described previously [18]. CD34 cells were
ositively selected using anti-CD34 beads, and re-
idual T cells were removed with a cocktail of anti-
D2, -CD6, and -CD7 antibody–coated beads.
he CD34 cell dose ranged from 2.45 to 15.90 
06/kg (median, 5.15  106/kg); the T-cell dose was
.2-1.0  105 CD3 cells/kg recipient weight. In the
bsence of GVHD or unless molecular remission was
ocumented in chronic myeloid leukemia, T cells
ere added back on days 45 and 100 (n  140) or on
ay 60 (n  6). The cyclosporine (CSA) dose varied
ccording to protocol; 36 patients received standard-
ose CSA (target plasma level, 200-400 ng/mL), 20
eceived low-dose CSA (target plasma level, 100-200
g/mL) starting on day 4 and continuing until an
ral dose was tolerated, and 90 received no CSA dur-
ng the ﬁrst 6 weeks after transplantation. All patients
tarted CSA either on day 44 (if T cells were added
ack on day 45) or on day 59 (if T cells were added
ack on day 60), and it was continued until at least day
30 (or longer, if chronic GVHD [cGVHD] occurred).
tandard prophylaxis against infection included ﬂu-
onazole to day 100, co-trimoxazole for 6 months,
nd weekly surveillance for cytomegalovirus antigen-
mia, as described previously [18,19]. Acute GVHD
aGVHD) was managed with high-dose steroids. Ste-
oid-refractory patients (ie, no response to 7 days of treatment) received combined treatment with anti–
umor necrosis factor (inﬂiximab) and anti-CD25 (da-
lizumab) monoclonal antibodies, as described previ-
usly [20].
tatistical Methods
We sought to estimate the relationship between
D34 dose and mortality in a ﬂexible way. Standard
pproaches, such as Cox proportional hazards models
ith linear effects, make strong assumptions about the
orm of the relationship between CD34 dose and
ortality (ie, that a change of 1 unit in CD34 dose
ill have the same relative effect on mortality for any
alue of CD34 dose). Therefore, the relationship of
D34 dose as a continuous variable and mortality
as modeled with a cubic spline representation for
D34 dose within a Cox proportional hazards model
21]. This approach allows for a smoothed represen-
ation of a continuous relationship between CD34
ose and mortality. The cubic spline terms were ﬁt
ith 2 knot points, which allowed for sufﬁcient ﬂexi-
ility with this relatively small sample size. We sought
o estimate the relationship between risk of mortality
nd CD34 dose. Models were ﬁt on (1) the whole
atient group and (2) by whether or not patients
eceived lung dose–reduced TBI.
Formal statistical inference was done using likeli-
ood ratio tests. We tested for a relationship between
D34 dose and mortality using a 2 test with 3 degrees
f freedom, both with and without adjustment for other
otential prognostic variables. We formally tested for
hether the relationship betweenCD34 dose andmor-
ality varied depending on other factors, such as lung
ose–reduced TBI, combined ventilation/diffusion ca-
acity (CVDC) deﬁcit (deﬁned as having both a forced
xpiratory volume in 1 minute [FEV1] and diffusing
apacity of the lung for CO [DLCO] of  100% pre-
icted), and age at transplantation by testing for a statis-
ical interaction between the spline terms of CD34 and
hese other factors.
Curves of the log hazard ratio (HR), relative to the
D34 dose corresponding to the worst survival in
hat group, were estimated. Efﬁcacious CD34 ranges
ere deﬁned as those corresponding to an HR of 
.5 (0.69 on the log scale) relative to the lowest
D34 dose in that group (ie, worst survival). This
ange corresponds to a doubling of the median sur-
ival relative to the lowest CD34 dose. For the lung
ose reduction group, we also present an efﬁcacious
D34 dose region corresponding to a 5-fold increase
n median survival, because the efﬁcacious region based
n a 2-fold increase was too wide to be useful.
Summary statistics, such as sample proportions,
edians, standard deviations, and 95% conﬁdence in-
ervals, were used to describe the patient characteris-
ics and the 1-year survival probabilities for patients in
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CD34 Dose and Risk of Mortality after TBI and PBSCT 341ifferent subgroups. Kaplan-Meier curves were used
o display the distributions of survival among sub-
roups of patients. Log-rank tests were used to com-
are survival curves. Data analysis was performed us-
ng S-PLUS version 7.0 statistical software (Insightful
orp, Seattle, WA).
ESULTS
Full demographic and outcomes data for this co-
ort have been reported previously [17]. Brieﬂy, me-
ian follow-up was 44 months (range, 12–90 months).
he 1-year overall survival was 70% in those treated
ith lung dose reduction and 64% in those treated
ithout lung dose reduction (P  .61). Survival of
atients treated with regimens A (85 patients), B (35
atients), and C (26 patients) did not differ signiﬁ-
antly.
A cubic spline Cox model, with 2 knot points
hroughout, was used to examine the relationship of
D34 dose and survival in more detail. Figure 1A
lots the log HR (relative to the lowest value of CD34,
hich was 2.45  106 cells/kg) as a function of log-
ransformed CD34 dose for all patients. Risk of mor-
ality decreased with CD34 doses between 4-8  106
ells/kg and then began to increase. On the original
cale, the dashed lines correspond to CD34 dose
alues of 5.1-12.9 106 cells/kg. Median survival over
his range was at least double the survival associated
ith the lowest CD34 dose. A statistical test of
hether CD34 dose was associated with survival
roduced a statistically signiﬁcant result (P  .002).
igure 1B shows an estimate of the relationship be-
ween CD34 and survival, adjusting for CVDC def-
cit, lung shielding, and age at transplantation. CD34
ose remained signiﬁcantly associated with survival
ven after these adjustments (P  .004). Furthermore,
he relationship as represented by the cubic spline was
early identical with and without adjustments.
We tested for interactions between CD34 dose
nd other important factors, such as lung dose–re-
uced TBI, CVDC deﬁcit, and age at transplantation.
he interactions of CD34 dose with lung dose–
educed TBI, CVDC deﬁcit, or age at transplantation
ere all statistically insigniﬁcant (P .35, .20, and .39,
espectively), demonstrating a lack of strong evidence
or a differential relationship between CD34 dose
nd mortality by these 3 factors.
However, because an examination of CD34
ose and mortality by type of TBI was of particular
nterest, we estimated the relationship separately by
ung dose–reduced TBI status. Figure 2 plots the
og HR (relative to the lowest value of CD34 dose
or no lung dose–reduced TBI) as a function of
og-transformed CD34 dose for patients with and
ithout lung dose –reduced TBI. The dose range tetween the vertical dashed lines correspond to a
-fold increase in median survival for those without
ung dose reduction and a 5-fold increase in median
urvival for those with lung dose reduction. On a
riginal scale, the dashed lines correspond to values
f 5.8-13.6  106 cells/kg (without lung dose re-
uction) and 4.3-10.2  106 cells/kg (with lung dose
eduction). Relative to the lowest CD34 dose in
he lung dose reduction group, the range corre-
ponding to a 2-fold increase in median survival for
his group was 3.3-14.3  106 cells/kg.
ISCUSSION
This article describes risk of mortality as a func-
igure 1. (A) A plot of the log HR (relative to the lowest value of
D34 for no lung dose–reduced TBI) as a function of log-trans-
ormed CD34 dose for all patients. On the original scale (expo-
entiated log values), the dashed lines correspond to CD34 dose
alues of 5.1 and 12.9  106 cells/kg. Median survival over this
ange was at least double the survival associated with the lowest CD
4 dose. The X value corresponds to the median CD34 dose on
he log scale. Dotted lines are pointwise 95% conﬁdence intervals.
B) This plot shows the relationship between CD34 dose and
ortality with adjustments for lung dose–reduced TBI, CVDC
eﬁcit, and age at transplantation.ion of CD34 dose, treated as a continuous variable,
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A. K. Singh et al.342uring PBSCT. Risk of mortality decreased with
D34 doses between 4–8 106 cells/kg and reached
minimum, with a subsequent rise at higher doses.
Other investigators have found similar ranges of
optimal” CD34 dose. Mohty et al. [12] suggested
hat to minimize the increased mortality from chronic
VHD but yet allow acceptable engraftment kinetics,
he optimum CD34 dose was 4–8  106 cells/kg.
aucha et al. [11] also suggested that increasing
D34 doses were signiﬁcantly associated with accel-
rated neutrophil (P .03) and platelet (P .01) en-
raftment, but higher CD34 doses ( 8.0  106
ells/kg) were also associated with a signiﬁcantly in-
reased hazard of extensive cGVHD (P .001). Based
n similar considerations, however, Kamel et al. [10]
uggested a higher but very narrow optimum CD34
ose range of 8.95–10  106 cells/kg.
Our data are very consistent with the ﬁndings of
ohty et al. [12], Zaucha et al. [11], and Kamel et al.
10]. Figure 3 shows our data with the dose ranges
uggested by these other investigators as dashed lines.
hese lines correspond exactly with the portion of the
igure 2. A plot of the log HR (relative to the lowest value of CD34
ose for patients with and without lung dose–reduced TBI. On the
ells/kg without lung dose reduction and 4.3 and 10.2  106 cells/k
o a doubling of median survival relative to the lowest CD34 value
urvival relative to the lowest CD34 value in the lung dose–reducurve with decreasing risk of mortality. bWhy the risk of mortality increases from a mini-
um point with increasing CD34 doses ( 8  106
ells/kg in this analysis) is unclear. CD34 cells are
nown to be a heterogeneous population in which the
rue “stem cell” subset has yet to be deﬁned [10].
hus, it remains possible that with higher CD34
oses, some population of cells that are deleterious to
urvival may be increased. Alternatively, because there
re only a few patients with doses 10 106 cells/kg,
his increase may be an artifact of the smoothing
rocedure.
Treatment-related factors also may affect survival
s a function of CD34 dose. With T-cell–replete
egimens, for example, T cell numbers may increase
ith increasing CD34 dose, resulting in increased
isk of GVHD [22]. However, the effect of T-cell dose
ay be less important in regimens that use G-CSF
11,23].
Further complicating matters, patient factors
lso interact with treatment-related factors. A re-
ent analysis of this cohort’s pretreatment ﬁndings
evealed that presence of a CVDC deﬁcit (deﬁned as
o lung dose–reduced TBI) as a function of log-transformed CD34
l scale, the dashed lines correspond to values of 5.8 and 13.6  106
lung dose reduction. These regions of lower mortality correspond
the no lung dose–reduction group and a 5-fold increase in median
oup. The dotted lines are pointwise 95% conﬁdence intervals. for n
origina
g with
withinoth FEV1 and DLCO  100% predicted) identi-
ﬁ
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CD34 Dose and Risk of Mortality after TBI and PBSCT 343ed a subgroup of patients who gained a signiﬁcant
20%) 1-year survival beneﬁt from the use of lung
ose–reduced TBI (70% vs 50%; P  .04, log-rank
est) [17].
Because no optimum conditioning regimen before
BSCT has yet been deﬁned, it is particularly impor-
ant that treatment-related factors are analyzed in the
ontext of each conditioning regimen. For all patients
n our cohort, CD34 doses of 5.1–12.9  106 cells/kg
esulted in at least a doubling of median survival as-
ociated with the lowest CD34 value. For patients
reated without lung dose reduction, this doubling of
edian survival occurred at a range of CD34 doses
f 5.8–13.6  106 cells/kg. For patients treated with
ung dose reduction, a similar range of CD34 doses
4.3–10.2  106 cells/kg) produced at least a 5-fold
mprovement from the survival associated with the
owest CD34 value. The magnitude of this change in
isk of mortality over a range of CD34 doses by type
f TBI used was not statistically signiﬁcant. However,
t is possible that the interaction test had low power,
nd a statistically signiﬁcant difference may be ob-
erved in a larger study.
The effect of treatment-related factors (eg, TBI,
-cell dose, and use of G-CSF) on mortality as a
unction of CD34 dose suggests that the stem cell
ose associated with minimum risk of mortality may
epend on the conditioning regimen used. Conse-
uently, analyses such as ours that treat CD34 doses
s a continuous variable might allow investigators to
etermine an optimal range of CD34 doses for their
igure 3. This is the same as Figure 1A. The ﬁrst 2 vertical dashed li
s found by Mohty et al. [12] The second and third vertical dashed
t al. [10]articular conditioning regimen.CKNOWLEDGMENTS
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